Key Pharmacogenomic Considerations for Sickle Cell Disease Patients

Area of Science:

• Pharmacogenomics
• Medical Genetics
• Clinical Pharmacology

Background:

• Sickle cell disease (SCD) presents a complex clinical phenotype, complicating patient stratification and management, particularly with hydroxyurea treatment.
• Theranostics, crucial for personalized medicine, remain underdeveloped in SCD research and clinical practice.
• Pharmacogenomics holds significant potential for tailoring SCD treatments.

Purpose of the Study:

• To review pharmacogenomic opportunities and challenges in sickle cell disease management.
• To explore pharmacogenomics in relation to pain management, genethics, and cost-effectiveness in SCD.
• To highlight the need for a holistic, patient-centric approach extending beyond hydroxyurea.

Main Methods:

• Literature synthesis from PubMed and Google Scholar.
• Keyword searches included "pharmacogenomics," "sickle cell disease," "hydroxyurea," "ethics," "pain management," and "cost-effectiveness."
• Inclusion criteria focused on English-language articles.

Main Results:

• Pharmacogenomic studies in SCD have primarily focused on hydroxyurea response variability.
• There is a need to expand pharmacogenomic applications to other SCD therapies and complications.
• Socioeconomic, ethical, and population variations present key challenges for future implementation.

Conclusions:

• Pharmacogenomics is essential for advancing personalized theranostics in sickle cell disease.
• Integrating pharmacogenomics requires addressing population variations, ethical considerations, and socioeconomic factors.
• Evidence-based clinical application necessitates urgent data on cost-effectiveness and population-specific ethics.